PROVIDED. Mass spectrometry has become the principal method to identify and characterize proteins and other macromolecular structures that are the functional machinery for biological processes. The purpose of the Mass Spectrometry &Proteomics Facility (MSPF) is to provide Cancer Center members with essential services in macromolecular structural analysis. These services include electrospray and MALDI mass spectrometry for molecular mass determination, tandem mass spectrometry (MSn) for detailed structure analysis (i.e., peptide sequencing), LC/MS/MS analysis for analyzing complex biological mixtures, and database searching for protein identification. The facility has two electrospray ion trap (LC/MS) systems (ThermoElectron LCQ and LTQ) and a high performance MALDI qToF system (PE/Sciex prOTof). The facility is operated both on a fee-for-service and shared use (researchers run their own samples) basis. Facility personnel provide expertise on sample preparation, analysis and data interpretation. They also assist experimental design and the development of novel methodologies. During the most recent 12-month reporting period, the CCMSPF was used by 19 Cancer Center members from all five Research Programs. Peer-reviewed usage represented 72% of total usage. Annual budget for this core is $408,887, of which 69% is institutional funding, 11% is user fees, and 20% ($81,000) is requested from the CCSG.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-29
Application #
8374884
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2013-04-24
Budget Start
2011-12-01
Budget End
2012-11-30
Support Year
29
Fiscal Year
2012
Total Cost
$105,330
Indirect Cost
$44,623
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Zhang, Bin; Nguyen, Le Xuan Truong; Li, Ling et al. (2018) Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. Nat Med 24:450-462
Kirschbaum, Mark H; Frankel, Paul; Synold, Timothy W et al. (2018) A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study. Br J Haematol 180:445-448
Zhang, Keqiang; Wang, Jinhui; Yang, Lu et al. (2018) Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1? and APC2 gene expression in non-small cell lung cancer. Mol Cancer 17:153
Liu, Liang; Yang, Lin; Yan, Wei et al. (2018) Chemotherapy Induces Breast Cancer Stemness in Association with Dysregulated Monocytosis. Clin Cancer Res 24:2370-2382
Woyach, Jennifer A; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med 379:2517-2528
Moreira, Dayson; Adamus, Tomasz; Zhao, Xingli et al. (2018) STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers. Clin Cancer Res 24:5948-5962
Choi, Audrey H; O'Leary, Michael P; Chaurasiya, Shyambabu et al. (2018) Novel chimeric parapoxvirus CF189 as an oncolytic immunotherapy in triple-negative breast cancer. Surgery 163:336-342
Golfetto, Ottavia; Wakefield, Devin L; Cacao, Eliedonna E et al. (2018) A Platform To Enhance Quantitative Single Molecule Localization Microscopy. J Am Chem Soc 140:12785-12797
Wolfson, Julie A; Richman, Joshua S; Sun, Can-Lan et al. (2018) Causes of Inferior Outcome in Adolescents and Young Adults with Acute Lymphoblastic Leukemia: Across Oncology Services and Regardless of Clinical Trial Enrollment. Cancer Epidemiol Biomarkers Prev 27:1133-1141
Wood, Kevin; Byron, Elizabeth; Janisch, Linda et al. (2018) Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. Am J Clin Oncol 41:963-966

Showing the most recent 10 out of 1396 publications